As a next step, cohort studies with long follow-up periods should be conducted to assess long-term outcomes, including glycemic

control. Third, the concentrations of glucose and insulin at 30 min were not measured and the insulinogenic index could not be calculated in the study [16, 17]. Further study is required with these measurements to examine early-phase insulin and glucagon secretion. Acknowledgments The ABT-263 mw authors thank the staff of Okamoto Medical Clinic for their excellent help in data collection. This study was funded by a 2012 Grant-in-Aid for Scientific Research (C) (No. 24590816). The authors take full responsibility for the content of the manuscript, participated in all stages of manuscript development, and approved the final manuscript for publication. AZD2014 purchase Conflict of interest All authors declare no conflict of interest. Compliance with ethics guidelines Study protocol was reviewed and approved by The Council of Okamoto Medical Clinic. All procedures followed were in accordance with ethical standards of responsible committee on human experimentation

(institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients in the study. The Council of Okamoto Medical Clinic reviewed and approved the research protocol. Author Contributions A.O. Foretinib ic50 designed and conducted the study and collected data. A.O. and H.Y. analyzed the data and wrote the manuscript. H.S. supervised the results. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References 1. D’Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab. 2011;13(Suppl 1):126–32.PubMedCrossRef 2. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. Selleck Fludarabine 2012;153:1039–48.PubMedCentralPubMedCrossRef 3. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 Suppl):S3–10.PubMedCrossRef 4. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.PubMedCrossRef 5. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef 6. Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–40.PubMedCrossRef 7. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab. 2010;12:700–8.PubMedCentralPubMedCrossRef 8.